News Archive

The FDA has approved the use of a potentially lifesaving foam on patients in a clinical trial at a Boston hospital.

Arsenal Medical has developed a foam system, called ResQFoam™, is designed to control acute hemorrhage. The way ResQFoam works is by injecting two liquid polymers, which together combine to create a foam. This foam quickly expands though actively flowing blood to compresses the injury and control bleeding. Upon undergoing surgery, the material is removed by the surgeon.

Countless military lives could be saved in the future thanks to a new remarkable foam. Made by Arsenal Medical and fittingly dubbed ResQ Foam, this remarkable innovation rapidly expands inside the body and seals off the wound.

Arsenal Medical announces today that they have received unconditional IDE approval from FDA to conduct a clinical study to examine the safety and effectiveness of ResQFoamTM, a self-expanding material for the treatment of severe internal bleeding in trauma patients.

An injectable foam that snakes through the abdomen is drawing big interest from the Pentagon, which hopes to use it to control bleeding from internal injuries on the battlefield. Arsenal Medical, a medical device firm based in Watertown, Mass., on Wednesday announced it had received $14 million from the US Army Medical Research and Materiel Command.

Arsenal Medical today announced that it has been granted a contract of more than $14 million to complete clinical and manufacturing development and the U.S. regulatory submission process to support product approval for its lead product candidate, ResQFoamTM.

This foam treatment is envisioned as an emergency “bridge to surgery” for warfighters who would otherwise die in the field.

Arsenal Medical and 480 Biomedical today announced $26.5 million in combined funding from a committed syndicate of investors to advance their respective product platforms. Arsenal Medical, a company developing novel, polymer based foam and nanofiber products, raised $16 million from Polaris Partners, North Bridge Venture Partners, and Intersouth Partners. 480 Biomedical, a clinical stage company developing innovative bioresorbable scaffold products, raised $10.5 million from the same syndicate in conjunction with a long term strategic investor. Both rounds included a conversion of debt, in addition to new equity financing.

It looks like a simple caulking gun. But it’s no ordinary tool. “The potential impact is truly revolutionary,” says Dr. David King.

The new technology may be able to extend life up to three hours.